Pulmonary Regurgitation clinical trials at UCLA
3 in progress, 1 open to eligible people
VenusP-Valve Pivotal Study (PROTEUS STUDY)
open to eligible people ages 12 years and up
A prospective, multi-center, non-randomized interventional study to evaluate the safety and effectiveness of the VenusP-ValveTM System in patients with native right ventricular outflow tract (RVOT) dysfunction. Post procedure, a clinical visit will be scheduled at pre-discharge, 30 days, 6 months, 12 months, and annually thereafter to 10 years. About 60 subjects will be enrolled in this study. Data analysis will be performed after all enrolled subjects complete 6-month follow-up and the primary endpoint analysis report will be submitted to FDA for PMA approval.
Irvine, California
ALTERRA: SAPIEN 3 THV With the Alterra Adaptive Prestent
Sorry, in progress, not accepting new patients
To demonstrate the safety and effectiveness of the Edwards Alterra Adaptive Prestent in conjunction with the Edwards SAPIEN 3 Transcatheter Heart Valve (THV) System in subjects with a dysfunctional right ventricular outflow tract/pulmonary valve (RVOT/PV) who are indicated for treatment of pulmonary regurgitation (PR). Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.
Los Angeles, California and other locations
Medtronic Harmony™ Transcatheter Pulmonary Valve Clinical Study
Sorry, in progress, not accepting new patients
The purpose of this study is to further evaluate the safety and effectiveness of the Harmony™ TPV system. The Pivotal/CAS phases of the study have transitioned into a post-approval study to confirm the long-term functionality of transcatheter implantation of the Medtronic Harmony TPV.
Los Angeles, California and other locations
Our lead scientists for Pulmonary Regurgitation research studies include Jamil A. Aboulhosn, MD.
Last updated: